Trial Profile
Phase I/IIa Study of Pharmacokinetics and Safety of Atorvastatin in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Atorvastatin (Primary)
- Indications Atherosclerosis; Coronary artery disease
- Focus Adverse reactions; Biomarker
- 02 Jul 2018 Status changed from recruiting to completed.
- 30 Apr 2018 Planned End Date changed from 1 Dec 2016 to 1 Mar 2019.
- 25 Feb 2013 Additional lead trial centres added as reported by ClinicalTrials.gov record.